Development Obligation. Subject to the limitations and other provisions set forth in this Section 3.1, the Parties intend that during the Term, Cubist shall continue to develop Licensed Products by conducting the Core Trials to support Regulatory Approval of Core IV Products in the United States. Additionally, subject to the limitations and other provisions set forth in this Section 3.1 Cubist shall use Commercially Reasonable Efforts to conduct (A) a [*] for the treatment of [*]; (B) a [*] for the treatment of [*]; (C) [*] in such territories and for such indications [*], having reasonably [*] of the Development Subcommittee; and (D) such additional clinical trials and preclinical studies for the IV Product and such additional formulations of Licensed Products as Cubist determines to conduct, [*] having reasonably [*] that the Development Subcommittee may make.
Appears in 1 contract
Sources: Marketing, Distribution and Development Agreement (Gilead Sciences Inc)
Development Obligation. Subject to the limitations and other provisions set forth in this Section 3.1, the Parties intend that during the Term, Cubist shall continue to develop Licensed Products by conducting the Core Trials to support Regulatory Approval of Core IV Products in the United States. Additionally, subject to the limitations and other provisions set forth in this
this Section 3.1 3.1, Cubist shall use Commercially Reasonable Efforts to conduct (A) a [*] [ ]* for the treatment of [[ ]*]; (B) a [*] [ ]* for the treatment of [[ ]*]; (C) [*] [ ]* in such territories and for such indications [[ ]*], having reasonably [*] [ ]* of the Development Subcommittee; and (D) such additional clinical trials and preclinical studies for the IV Product and such additional formulations of Licensed Products as Cubist determines to conduct, [*] [ ]* having reasonably [*] [ ]* that the Development Subcommittee may make.
Appears in 1 contract
Sources: Marketing, Distribution and Development Agreement (Cubist Pharmaceuticals Inc)